The Hologic Whole Body DXA Reference Database software used on Hologic QDR bone densitometers measures the regional and whole body bone mineral density, lean and fat tissue mass and calculates derivative values of bone mineral content, area, soft tissue mass, regional soft tissue mass, total soft tissue mass, fat free mass, regional and total soft tissue mass ratios, % fat, regional % fat, total body % fat, android % fat, gynoid % fat, android/gynoid ratio, and body mass index. The values can be displayed in user-defined statistical formats and trends with color image mapping, and compared to reference populations at the sole discretion of the health care professional.

These body composition values are useful to health care professionals in their management of diseases and conditions where the disease or conditions itself, or its treatment, can affect the relative amounts of fat and lean tissue. The Hologic Whole Body DXA Reference Database software does not diagnose disease, recommend treatment regimens, or quantify treatment effectiveness. Only the health care professional can make these judgments. Some of the diseases and conditions for which body composition values are useful include chronic renal failure, anorexia nervosa, obesity, AIDS/HIV, and cystic fibrosis. DXA body composition is a useful alternative to hydrostatic weighting and skin fold measurements.

Device Description

AI/ML Overview

The provided text is a 510(k) summary for the Hologic Whole Body DXA Reference Database. It does not contain information about acceptance criteria or a study that proves the device meets specific performance metrics. Instead, the submission focuses on demonstrating substantial equivalence to a predicate device.

Here's a breakdown of what is in the document, and what is missing based on your request:

What is present in the document:

Device Identification: Hologic Whole Body DXA Reference Database.
Intended Use: Measures regional and whole body bone mineral density, lean and fat tissue mass, and calculates derivative values for comparison to reference populations. It's for healthcare professionals to manage diseases/conditions affecting fat and lean tissue, not for diagnosis or treatment effectiveness quantification.
Classification: Class II, Bone Densitometer, Product Code KGI.
Predicate Device: Body Composition Software Option for GE Lunar DEXA Bone Densitometers (K071570).
Conclusion of Substantial Equivalence: The Hologic Whole Body DXA Reference Database does not change algorithms/measured values from previously cleared software (APEX 2.0 Software K072847), fundamental scientific technology, or raise new safety/efficacy concerns. It is substantially equivalent to the predicate device.

What is NOT present in the document, and therefore cannot be reported:

A table of acceptance criteria and the reported device performance: This document explicitly states that the device "does not change any of the algorithms or measured values" from a previously cleared software (APEX 2.0 Software, K072847). This 510(k) is based on demonstrating substantial equivalence because no changes were made to the core algorithms, rather than presenting new performance data against specific acceptance criteria for a new or modified device.
Sample size used for the test set and the data provenance: No new test set data is provided, as the submission relies on the unchanged algorithms from a previously cleared device.
Number of experts used to establish the ground truth for the test set and their qualifications: Not applicable, as no new test set is presented.
Adjudication method for the test set: Not applicable.
Multi-reader multi-case (MRMC) comparative effectiveness study: No MRMC study is mentioned. The submission is based on the system's underlying algorithms being unchanged and previously cleared.
Standalone (i.e., algorithm only without human-in-the-loop performance) study: No new standalone study is performed or reported in this document for the reasons stated above.
The type of ground truth used: Not applicable, as no new study requiring ground truth establishment is described.
The sample size for the training set: Not applicable, as this submission is not about training a new algorithm or presenting new performance metrics.
How the ground truth for the training set was established: Not applicable.

In summary: The provided document is a 510(k) summary demonstrating substantial equivalence based on the lack of change to previously cleared software algorithms and measured values, rather than presenting new performance data against specific acceptance criteria for the "Hologic Whole Body DXA Reference Database" as a new or modified device with altered performance. Therefore, the information requested regarding acceptance criteria and performance studies is not contained within this particular submission.

Summary

{0}------------------------------------------------

Hologic, Inc .: November 3, 2010

F. 510(k) Summary

MAR 1 6 2011

Manufacturing Establishment and Contact Information F.1

Manufacturer Name and Address: F.1.1

Hologic. Inc. 35 Crosby Drive Bedford, MA 01730

F.1.2 Establishment Registration Number:

1221300

F.1.3 Name, Title, and Telephone Number of Contact:

Christina Hurton Regulatory Affairs Specialist Phone: (781) 999-7781 Fax: (866) 652-8674 Christina.Hurton@hologic.com

F.2 Device Identification

F.2.1 Device Trade Name:

Hologic Whole Body DXA Reference Database

F.2.2 Common / Usual Name:

Database for Bone Densitometers

Proposed Intended Use: F.2.3

{1}------------------------------------------------

K103265
P. 2 of 2

Hologic, Inc.: November 3, 2010

these judgments. Some of the diseases and conditions for which body composition values are useful include chronic renal failure, anorexia nervosa, obesity, AIDS/HIV, and vistic fibrosis. DXA body composition is a useful alternative to hydrostatic weighting and skin fold measurements.

F.3 Device Classification

F.3.1 Classification:
Class II

F.3.2 Classification Name and Rule

Bone Densitometer: 21 CFR 892.1170

F.3.3 Classification Panel
Radiology
F.3.4 Product Code
90 KGI

F.3.5 Predicate Devices

o 510(k) No .: K071570 Trade Name: Body Composition Software Option for GE Lunar DEXA Bone Densitometers June 27, 2007 SE Date: Manufacturer: GE Medical Systems, Lunar

F.4 Conclusion:

The Hologic Whole Body DXA Reference Database does not change any of the algorithms or measured values of fat mass, lean mass or bone mass from the previously cleared APEX 2.0 Software (K072847). It does not change the fundamental scientific technology and no new safety or efficacy concerns are raised.

The Hologic Whole Body DXA Reference Database is substantially equivalent to the presently marketed predicate device: Body Composition Software Option for GE Lunar DEXA Bone Densitometers (K071570).

में

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the logo for the Department of Health & Human Services USA. The logo features a stylized eagle with three stripes representing the three branches of government. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circular pattern around the eagle.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002

Ms. Christina Hurton Regulatory Affairs Specialist Hologic, Inc. 35 Crosby Drive BEDFORD MA 01730

MAR 1 6 2011

Re: K103265

Trade/Device Name: Hologic Whole Body DXA Reference Database Regulation Number: 21 CFR 892.1170 Regulation Name: Bone Densitometer Regulatory Class: II Product Code: KGI Dated: November 3, 2010 Received: November 26, 2010

Dear Ms. Hurton:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

{3}------------------------------------------------

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office

of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely Yours,

Mary Pastel

Mary S. Pastel, Sc.D. Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

P. 1 of 1

Hologic, Inc .: November 3, 2010

Hologic Whole Body DXA Reference Database 510(k) Premarket Notification

A.2 Indication for Use Statement

510(k) Number (if known): K 103 2105

Device Name:

Hologic Whole Body DXA Reference Database

Indication for Use:

The Hologic Whole Body DXA Reference Database software used on Hologic ODR bone densitometers measures the regional and whole body bone mineral density, lean and fat tissue mass and calculates derivative values of bone mineral content, area, soft tissue mass, regional soft tissue mass, total soft tissue mass, fat free mass, regional and total soft tissue mass ratios, % fat, regional % fat, total body % fat, android % fat, gynoid % fat, android/gynoid ratio, and body mass index. The values can be displayed in user-defined statistical formats and trends with color image mapping, and compared to reference populations at the sole discretion of the health care professional.

Prescription Use X (Part 21 CFR 801 Subpart D): AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Mary S Pasto
(Division Sign-Off)

510K. K103265

Regulation Number and Section

§ 892.1170 Bone densitometer.

(a)
Identification. A bone densitometer is a device intended for medical purposes to measure bone density and mineral content by x-ray or gamma ray transmission measurements through the bone and adjacent tissues. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.